Published in:
Open Access
01-12-2010 | Research article
Gel-type autologous chondrocyte (Chondron™) implantation for treatment of articular cartilage defects of the knee
Authors:
Nam-Yong Choi, Byoung-Woo Kim, Woo-Jin Yeo, Haeng-Boo Kim, Dong-Sam Suh, Jin-Soo Kim, Yoon-Sik Kim, Yong-Ho Seo, Jea-Yeong Cho, Chung-Woo Chun, Hyun-Shin Park, Asode Ananthram Shetty, Seok-Jung Kim
Published in:
BMC Musculoskeletal Disorders
|
Issue 1/2010
Login to get access
Abstract
Background
Gel-type autologous chondrocyte (Chondron™) implantations have been used for several years without using periosteum or membrane. This study involves evaluations of the clinical results of Chondron™ at many clinical centers at various time points during the postoperative patient follow-up.
Methods
Data from 98 patients with articular cartilage injury of the knee joint and who underwent Chondron™ implantation at ten Korean hospitals between January 2005 and November 2008, were included and were divided into two groups based on the patient follow-up period, i.e. 13~24-month follow-up and greater than 25-month follow-up. The telephone Knee Society Score obtained during telephone interviews with patients, was used as the evaluation tool.
Results
On the tKSS-A (telephone Knee Society Score-A), the score improved from 43.52 ± 20.20 to 89.71 ± 13.69 (P < 0.05), and on the tKSS-B (telephone Knee Society Score-B), the score improved from 50.66 ± 20.05 to 89.38 ± 15.76 (P < 0.05). The total improvement was from 94.18 ± 31.43 to 179.10 ± 24.69 (P < 0.05).
Conclusion
Gel-type autologous chondrocyte implantation for chondral knee defects appears to be a safe and effective method for both decreasing pain and improving knee function.